Methadone vs. buprenorphine vs. naltrexone: MAT documentation requirements under N.J.A.C. 8:43K and 42 CFR Part 8

An opioid treatment program in New Jersey answers to two sets of rules: the federal rule for opioid treatment programs, 42 CFR Part 8, and the state's licensing and program rules, N.J.A.C. 8:43K and 10:36. Both ask for documentation, and part of it depends on the medication. Here is what applies to every patient, what differs for methadone, buprenorphine and naltrexone, what New Jersey adds, and how Zoobook handles it.

The medications and the rules

The federal rule calls medication for addiction treatment "medications for opioid use disorder", or MOUD. Within an opioid treatment program (OTP), it counts three as approved: methadone; buprenorphine and buprenorphine combination products approved for opioid use disorder; and naltrexone (42 CFR 8.12(h)(2)).

42 CFR Part 8 sets the standards an OTP must meet as a condition of its federal certification (42 CFR 8.12(a)). In New Jersey, an OTP also follows the state's OTP section, N.J.A.C. 8:43K-8.1, and the program standards for OTP services in N.J.A.C. 10:36. Where a standard in N.J.A.C. 10:36 and a federal standard conflict, the more restrictive one governs (10:36-9.1(e)).

What every patient's record needs in an OTP

• The admission decision. Qualified staff determine, using accepted medical criteria, that the person meets the diagnostic criteria for a moderate to severe opioid use disorder, and has an active disorder, is in remission, or is at high risk of recurrence or overdose. That decision is documented in the clinical record. The patient chooses treatment voluntarily and gives informed consent (42 CFR 8.12(e)(1)). A patient under 18 needs the written consent of a parent, guardian or responsible adult, unless state law lets minors consent on their own (42 CFR 8.12(e)(2)).
• The initial medical examination. A screening examination comes before treatment starts, and a full in-person physical examination, with serology and other clinically appropriate tests, within 14 calendar days of admission. An examination done outside the OTP is sent to the OTP and verified by an OTP practitioner (42 CFR 8.12(f)(2)).
• The assessment and the care plan. Within 14 calendar days of admission: a physical and behavioral health assessment, including screening for imminent risk of harm to self or others, and a care plan with the patient's goals, the actions agreed with the patient, including harm reduction, and how often services are to be provided. The plan is reviewed and updated as treatment goes on (42 CFR 8.12(f)(4)(i)).
• A yearly physical examination, which the rule says should be documented in the clinical record (42 CFR 8.12(f)(4)(ii)).
• Drug testing: at least eight random drug tests a year for each patient, allowing for extenuating circumstances, using tests with FDA marketing authorization (42 CFR 8.12(f)(6)).
• The record itself: a recordkeeping system adequate to document and monitor care, that meets federal and state reporting requirements and keeps records confidential, and a note in each record of the OTP's good-faith effort to find out whether the patient is enrolled in another OTP (42 CFR 8.12(g)).
• Deviations from labeling. Each medication is given in line with its FDA-approved labeling, and any significant deviation in dose, frequency or conditions of use is documented in the patient's record (42 CFR 8.12(h)(4)).
• Tapering. A patient who chooses to taper does so with informed consent at a mutually agreed rate, and the treating practitioner documents that consent in the clinical record (42 CFR 8.12(e)(3)).
• Take-home doses. Any patient may take home doses for days the clinic is closed. Beyond that, a decision to give take-home doses, and its basis under the rule's criteria, is documented in the medical record, and the rule asks that the patient's education on transporting and storing them safely be documented too (42 CFR 8.12(i)).

What differs by medication

Sources: 42 CFR 8.12(f)(2)(v), (h)(3), (h)(4) and (i).

What New Jersey adds

• Opioid treatment programs hold federal certification, a DEA registration and a state registration for controlled dangerous substances, provide 24-hour emergency telephone coverage, and keep written methadone withdrawal policies within the rule's taper limits (8:43K-8.1).
• The taper limits. For clients starting at 100 mg a day, the methadone dose may be reduced by no more than 10 mg every two days. For clients receiving more than 100 mg a day, it may be reduced by no more than 20 percent of the starting dose every two days until the dose is 100 mg or less; after that, it may be reduced faster than 10 mg every two days (8:43K-8.1(a)5, as adopted).
• Medication education and monitoring. Patients prescribed medication receive education on its benefits, side effects and risks, such as methadone-induced cardiac arrhythmia, and the program monitors their treatment response, side effects and health indicators (10:36-5.6(b)).
• Naloxone. Every patient with a history of opioid use receives a take-home supply of an opioid antidote, a prescription, or information on how to get one (8:43K-5.1(b)7).
• Involuntary discharge. Before an involuntary discharge, an OTP tries to place the patient elsewhere, manages withdrawal, gives overdose education and information on reversal medication, and keeps medication going during an internal appeal. A patient's refusal is documented in the treatment record (10:36-9.2).

If you give buprenorphine outside an OTP

A licensed facility that is not an OTP, but stores and administers controlled medications to treat substance use, including withdrawal management and initial stabilization in an outpatient setting, follows its own subchapter of 8:43K (8:43K-10.1). Among other things, it:

• documents a health screening at admission, including the patient's clinical appropriateness for these medications under DSM-5 criteria and the medical director's protocols, and the patient's willingness to take part (8:43K-10.2(a)3);
• gives each patient a plan of care for medical, psychiatric and social needs, reviewed at least every three months in the first year and every six months after (8:43K-10.2(a)4);
• keeps drug-specific withdrawal management protocols that name the withdrawal assessment instruments, the medications and how often vital signs are checked (8:43K-10.3).

How Zoobook handles it

• Methadone and MAT. Dose tracking for manual pumps and automated dispensing systems, take-home sorting, missed-dose alerts and reports in one click. Dosing takes 1 to 2 minutes per patient.
• Built around your workflows. Zoobook can be customized to fit your programs' workflows, buprenorphine and naltrexone treatment and psychiatric care included.
• ePrescribe. ePrescribe is included.
• Telehealth built in. Video and phone visits, through the Zoom integration.
• Outcomes and analytics. Built-in reports on retention, treatment plan completion, no-show rates and drug screen trends, and a report builder for measures of your own, such as discharge outcomes, readmissions and patient satisfaction.
• Privacy and consent before sharing. HIPAA and 42 CFR Part 2 controls, hosted on Amazon Web Services with encryption. Zoobook keeps consent forms and checks them before information leaves the record, for example before a referral source is notified or before a client's record is sent to a health information network.
• Getting started in New Jersey. Implementation takes 30 days for a small facility, 60 for a medium one and 90 for an enterprise. For a New Jersey facility, Zoobook's team sets up your NJSAMS connection, loads consent forms for sharing addiction treatment records under 42 CFR Part 2, and provides assessment and treatment-plan templates for the state's new rule.

This article describes federal and New Jersey rules in plain words and is not legal or clinical advice. The official texts are 42 CFR Part 8 (Code of Federal Regulations, revised as of October 1, 2025), the Department of Health's adoption notice for N.J.A.C. 8:43K (58 N.J.R. 4(1), April 6, 2026) and the DMHAS adoption notice for N.J.A.C. 10:36 (58 N.J.R. 1382(a)).